Clinical trials
Lung Cancer (NSCLC) clinical trials
Below are recruiting lung cancer (nsclc) clinical trials, each written for real people, not researchers. We’re tracking 1,092 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06758557RecruitingPhase 1/Phase 2
HB0025 for advanced solid tumors
This trial tests a new drug called HB0025 for people with advanced non-small cell lung cancer or endometrial cancer that cannot be removed by surgery. The study aims to see if the drug is safe and effective.
Baoding, HebeiAges 18–75 - NCT07046923RecruitingPhase 1
A study of LY4175408 for advanced cancer
This trial tests a new targeted drug (LY4175408) for people with certain advanced solid tumors (lung, endometrial, or triple negative breast cancer) who have already tried standard treatments. The goal is to see if the drug is safe and effective.
Stanford, CaliforniaAges 18 years+ - NCT06532591RecruitingPhase 2
Cadonilimab plus chemo before and after lung cancer surgery
This trial tests a new immunotherapy drug (cadonilimab) combined with standard chemotherapy, given before and after surgery for lung cancer that has very low PD-L1. The goal is to see if this combination helps shrink the tumor and prevents it from coming back.
Chengdu, SichuanAges 18–70 - NCT04114136RecruitingPhase 2
Study tests pembrolizumab or nivolumab plus a diabetes-like drug
This Phase 2 study tests whether adding a metabolic (diabetes-related) medicine to an immune therapy (pembrolizumab or nivolumab) can better control certain solid tumors. It may help people whose standard treatment would usually be pembrolizumab or nivolumab alone.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05686434RecruitingPhase 2
Osimertinib after surgery for early-stage EGFR-mutated lung cancer
This trial tests osimertinib (a targeted pill) given after surgery to help prevent early-stage lung cancer from coming back. It’s for people with fully removed, high-risk stage I non-small cell lung cancer that has specific EGFR gene changes.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06241807RecruitingPhase 2
Camrelizumab plus chemo before surgery for stage III lung cancer
This trial tests adding the immunotherapy drug camrelizumab to standard chemotherapy before surgery for people with stage IIIA-IIIB non-small cell lung cancer. The goal is to see if this combination shrinks tumors more effectively before removal.
Jinan, ShandongAges 18–75 - NCT07314216RecruitingPhase 2
Firmonertinib plus radiation for stage III lung cancer with rare EGFR mutations
This trial tests whether combining the targeted pill firmonertinib with radiation therapy can help people with stage III non-small cell lung cancer that has certain rare EGFR mutations. It is for those whose cancer cannot be removed by surgery.
Changsha, HunanAges 18 years+ - NCT06221670RecruitingPhase 2
Toripalimab after surgery for high-risk early lung cancer
This trial tests whether giving a drug called Toripalimab after surgery can help prevent early-stage non-squamous non-small cell lung cancer from coming back. It is for people whose tumors have high-risk features and PD-L1 levels of at least 1%.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06945705RecruitingPhase 2
Targeted therapy for EGFR-mutant lung cancer with brain spread
This trial tests a combination of two targeted pills (furmonertinib and anlotinib) as a first treatment for people with advanced EGFR-mutant non-small cell lung cancer that has spread to the brain. It aims to see if this combination works better than the standard approach for controlling the cancer.
ZhengzhouAges 18 years+ - NCT07586202RecruitingPhase 2
Testing New Drug Combinations Before Lung Cancer Surgery
This trial tests whether giving new drugs (amivantamab plus either lazertinib or chemotherapy) before surgery helps people with a specific type of lung cancer that can be removed. The goal is to shrink tumors and improve surgery outcomes.
Toronto, OntarioAges 18 years+ - NCT05498064Recruiting
Study of ensartinib for advanced ALK-positive lung cancer
This real-world study looks at how ensartinib works in people with advanced ALK-positive non-small cell lung cancer (NSCLC) whose disease has continued or worsened after ALK-targeted therapy. It may help doctors understand how well the treatment works and who benefits most in everyday care.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05805631RecruitingPhase 2
Pemetrexed into spinal fluid for EGFR-mutant lung cancer spread to brain lining
This Phase 2 trial tests giving pemetrexed directly into the spinal fluid to treat cancer that has spread to the brain’s and spinal cord’s lining (leptomeningeal metastasis). It is for people with EGFR-mutant non-squamous lung cancer whose disease progressed after osimertinib, and who may benefit from a targeted treatment delivered to the area affected in the brain lining.
Taipei, TaiwanAges 20 years+ - NCT06623656RecruitingPhase 2
Pre-surgery treatment comparison for non-small cell lung cancer
This trial compares two treatment approaches before surgery for non-small cell lung cancer (NSCLC): radiation plus immunotherapy versus chemotherapy plus immunotherapy. The goal is to see which combination works better to shrink the tumor before it is removed.
New York, New YorkAges 18 years+ - NCT06709859RecruitingPhase 2
Afatinib plus chemo for unresectable stage III lung cancer
This trial tests whether combining afatinib (a targeted pill for EGFR mutations) with chemotherapy can shrink advanced stage III non-small cell lung cancer (NSCLC) enough to make surgery possible. It is for people whose cancer has not been treated yet and has a specific EGFR mutation.
Jinan, ShangdongAges 18 years+ - NCT06908304RecruitingPhase 3
Study of THIO + Cemiplimab vs Chemo for Advanced Lung Cancer
This trial tests a new combination of drugs (THIO and cemiplimab) against standard chemotherapy for people with advanced non-small cell lung cancer who have already tried two prior treatments including immunotherapy and platinum chemo. The goal is to see if the combination helps control the cancer better.
PoznanAges 18 years+ - NCT03351842RecruitingPhase 2
Surgery alone or plus chemotherapy for early lung cancer
This trial studies whether adding chemotherapy after surgery helps people with early-stage lung adenocarcinoma that has a micropapillary pattern. It’s testing whether chemotherapy given after complete tumor removal can improve outcomes compared with surgery alone.
ShanghaiAges 19–70 - NCT07339254Recruiting
Survey about immunotherapy for lung cancer patients
This study is a survey to learn about the experiences and feelings of people with non-small cell lung cancer who are taking immunotherapy drugs. The goal is to understand how you're doing on treatment, which can help improve care for others.
Los Angeles, CaliforniaAges 18 years+ - NCT06317558Recruiting
Real-world study of immunotherapy before surgery for lung cancer
This study looks at how well immunotherapy given before surgery works for non-small cell lung cancer. It aims to help doctors understand real-world outcomes for patients who receive this treatment.
Beijing, Beijing MunicipalityAges 18–85 - NCT06317324Recruiting
SBRT vs. surgery for lung cancer with lobe spread
This study compares two treatments—stereotactic body radiation (SBRT) and surgery—for people whose non-small cell lung cancer has spread into the tissue between the lobes of the lung. The goal is to see which treatment leads to better long‑term results for this specific type of cancer.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT05266846RecruitingPhase 2
Immunotherapy plus anti-angiogenesis and chemo for ALK lung cancer
This Phase 2 trial tests pembrolizumab (an immune therapy), bevacizumab (a medicine that blocks blood-vessel growth), and chemotherapy in people with ALK-rearranged lung cancer that is still present after the first treatment with alectinib. It aims to shrink tumors and improve control of the cancer.
Changsha, HunanAges 18 years+ - NCT05715229RecruitingPhase 2
Blood test–guided treatment choice for advanced lung cancer
This Phase 2 study tests how results from blood cancer DNA tests (ctDNA) can help choose the best immune therapy approach for newly diagnosed, advanced lung cancer. It aims to improve outcomes by matching treatment decisions to a patient’s immune and blood test “profile.”
Washington D.C., District of ColumbiaAges 18 years+ - NCT07330037RecruitingPhase 2
TIL plus immunotherapy for NSCLC without complete response after chemoimmunotherapy
This trial tests a new treatment for people with non-small cell lung cancer (NSCLC) that was removed by surgery but did not completely disappear after pre-surgery chemoimmunotherapy. The treatment combines your own tumor-fighting cells (L-TIL, grown from your tumor) with an immunotherapy drug (tislelizumab) to try to keep the cancer from coming back.
Tianjin, Tianjin MunicipalityAges 17–75 - NCT06156527RecruitingPhase 2
Lazertinib alone vs lazertinib plus Avastin for EGFR+ lung cancer in smokers
This trial tests if adding bevacizumab (Avastin) to lazertinib works better than lazertinib alone for advanced non-small cell lung cancer with an EGFR mutation. It is for people who have smoked at least 100 cigarettes in their lifetime.
Suwon, Gyeonggi-doAges 19 years+ - NCT07186699Recruiting
Understanding lung cancer in people with past alcohol or drug use
This study looks at the experiences of people with lung cancer (NSCLC) who also have a history of alcohol or drug use. It aims to help doctors better understand and support patients facing both challenges.
Los Angeles, CaliforniaAges 18 years+
Hear when a new Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer (nsclc)?
- Yes. Clin2 currently lists 1,092 recruiting lung cancer (nsclc) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer (nsclc) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer (nsclc) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.